Intrexon Corp (NYSE:XON) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report issued on Thursday.

XON has been the topic of a number of other research reports. Wunderlich cut their target price on shares of Intrexon Corp from $50.00 to $35.00 and set a “buy” rating on the stock in a research note on Tuesday, March 14th. Zacks Investment Research upgraded shares of Intrexon Corp from a “hold” rating to a “buy” rating and set a $24.00 target price on the stock in a research note on Tuesday, May 2nd. Finally, Stifel Nicolaus restated a “buy” rating and issued a $57.00 target price on shares of Intrexon Corp in a research note on Tuesday, April 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $40.96.

Analyst Recommendations for Intrexon Corp (NYSE:XON)

Shares of Intrexon Corp (NYSE XON) opened at 22.56 on Thursday. The stock has a 50 day moving average price of $22.25 and a 200 day moving average price of $22.94. The firm’s market capitalization is $2.70 billion. Intrexon Corp has a 52 week low of $18.41 and a 52 week high of $32.90.

Intrexon Corp (NYSE:XON) last posted its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by $0.04. The firm had revenue of $53.70 million during the quarter, compared to analysts’ expectations of $49.08 million. Intrexon Corp had a negative net margin of 51.04% and a negative return on equity of 23.13%. The business’s quarterly revenue was up 23.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.55) earnings per share. Equities analysts forecast that Intrexon Corp will post ($0.92) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/06/19/intrexon-corp-xon-stock-rating-upgraded-by-bidaskclub.html.

Large investors have recently modified their holdings of the stock. Norges Bank bought a new stake in shares of Intrexon Corp during the fourth quarter worth about $17,300,000. Michael & Susan Dell Foundation acquired a new stake in Intrexon Corp during the fourth quarter valued at $10,519,000. CWM LLC raised its stake in Intrexon Corp by 9,455.4% in the first quarter. CWM LLC now owns 35,546 shares of the biotechnology company’s stock valued at $705,000 after buying an additional 35,174 shares during the period. Private Advisor Group LLC raised its stake in Intrexon Corp by 18.6% in the first quarter. Private Advisor Group LLC now owns 35,502 shares of the biotechnology company’s stock valued at $672,000 after buying an additional 5,556 shares during the period. Finally, Capital Fund Management S.A. raised its stake in Intrexon Corp by 40.9% in the first quarter. Capital Fund Management S.A. now owns 127,798 shares of the biotechnology company’s stock valued at $2,533,000 after buying an additional 37,098 shares during the period. Institutional investors and hedge funds own 84.94% of the company’s stock.

Intrexon Corp Company Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Receive News & Stock Ratings for Intrexon Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corp and related stocks with our FREE daily email newsletter.